Pharmacogenomic Strategies for Personalised Medicine (PGxPM2025)

Approaches that address one or more of the following aspects:

• Identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
• Validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
• Use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).

Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.

Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.

Establish participatory research, i.e. active representation of patients or citizens as part of research projects.
Research projects in all disease areas will be welcome (All text is taken directly from https://www.eppermed.eu/news-events/news/ep-permed-jtc2025-pre-announcement-pharmacogenomic-strategies-for-personalised-medicine-pgxpm2025/) 

If private entities are the recipients of support, the state aid regulations must be followed, and it will be granted under the General Block Exemption Regulation Article 25. It is possible to apply for support for up to 50 percent of the eligible costs.